MedinCell S.A (MDCLF PINK) stock market data APIs
$6.9819
0(0%)
as of May 7, 2025
MedinCell S.A Financial Data Overview
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Prev. Close
6.9819
Open
6.9819
High
6.9819
Low
6.9819
52 wk Range
6.9757-6.976
Market Cap
231 M
Shares Outstanding
33 067 K
Revenue
13 200 K
EPS
-0.2722
Beta
1.272
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MedinCell S.A data using free add-ons & libraries
Get MedinCell S.A Fundamental Data
MedinCell S.A Fundamental data includes:
- Net Revenue: 13 200 K
- EBITDA: -18 810 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-09-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MedinCell S.A News
New
European Growth Companies With High Insider Ownership In April 2025
As trade tensions between the U.S. and China show signs of easing, European markets have responded positively, with major indices like Germany's DAX and France's CAC 40 seeing notable gains. Against t...
MedinCell’s Partner Teva Announces Successful Launch of UZEDY™
MONTPELLIER, France, August 02, 2023--(BUSINESS WIRE)--MedinCell (Paris:MEDCL): Access here the complete press release During today’s Q2 earnings call, Richard Francis, President and CEO of Teva, ...
MedinCell has Received the Last Tranche of €10m from the European Investment Bank (EIB) Loan
MONTPELLIER, France, July 31, 2023--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): The drawdown of this last tranche of a 40 million euros total loan signed with the EIB in November 2022...
MedinCell Announces the Availability of Its 2022-23 Universal Registration Document Including the Annual Financial Report
MONTPELLIER, France, July 31, 2023--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): The 2022-23 Universal Registration Document (URD) filed with the French market authority (Autorités de...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
